Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Domestic business expected to grow in 2026, driven by stricter enforcement, volume growth, strong product pipeline, and stabilized API prices. The company expects significant growth from new contracts starting 2026, including INR 200+ crores from Zambian supplies and INR 300+ crores combined from Zambia and European supply in 2027.
From Akums Drugs & Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Domestic business expected to grow in 2026, driven by stricter enforcement, volume growth, strong product pipeline, and stabilized API prices.
- Additional revenue of approx. INR 200 crores expected from Zambian supplies starting 2026.
- Around INR 300 crores annual revenue projected from combined Zambian and European supplies from 2027.
- Fully operational Zambian facility anticipated to generate $40-50 million starting 2029.
- European CDMO contract for oral liquid formulations to start commercial supply from April 2027 with six-year tenure.
- European market expansion underway with multiple dossiers (~10) being filed across plants for self-marketing or out-licensing.
- Volume growth recorded at 7% in recent quarters, with efforts on expanding product basket and client penetration.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capex focused mainly on dosage forms, including new injectable facilities, with INR 107 crores spent in H1 FY26 and expectation of INR 100-125 crores in the next six months.
- Past Jammu plant capex on hold due to legislative changes.
- Additional capex planned to be mindful and future-ready, focusing on utilized or potential market growth segments.
- No immediate close inorganic acquisitions, but actively exploring profitable businesses with dosage form or export market capabilities, working with bankers.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has secured a large European CDMO contract involving multiple SKUs of oral liquid formulations, starting commercial supplies around April 2027, with a six-year tenure.
- They have secured over 10 dossiers for European markets, including out-licensing or self-marketing opportunities.
- Positive traction is seen with increased minimum order quantities (MOQs) and new leads from Nordics, Western, and Eastern Europe.
- The Zambia JV contract will contribute additional turnover starting 2026 (~INR 200 crores) and will scale up to $40-50 million annual revenue by 2029.
- The company is actively working on pipeline products and expanding their export business beyond current contracts.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q2 FY26 results?
Domestic business expected to grow in 2026, driven by stricter enforcement, volume growth, strong product pipeline, and stabilized API prices. The company expects significant growth from new contracts starting 2026, including INR 200+ crores from Zambian supplies and INR 300+ crores combined from Zambia and European supply in 2027.
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.7 with a market cap of ₹11,512 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
Ongoing capex focused mainly on dosage forms, including new injectable facilities, with INR 107 crores spent in H1 FY26 and expectation of INR 100-125 crores in the next six months.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.